| Role of 5α-Reductase Inhibitors in Prostate Cancer Prevention and Treatment. | |
| | |
MedLine Citation:
|
PMID: 22446342 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
Although testosterone is the most abundant serum androgen, dihydrotestosterone is the main prostatic androgen. Testosterone is converted to dihydrotestosterone by the enzyme 5α-reductase (5α-R). Dihydrotestosterone plays an important role in several human diseases, including benign prostate enlargement and prostate cancer. The observation that males born with 5α-R 2 deficiency have never been reported to develop prostate cancer stimulated interest in development of 5α-R inhibitors. Thus far, 2 5α-R inhibitors are approved for clinical use. Several trials evaluated the use of 5α-R inhibitors in prostate cancer prevention and treatment and will be reviewed in this article. |
| | |
Authors:
|
Faris Azzouni; James Mohler |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2012-3-23 |
Journal Detail:
|
Title: Urology Volume: - ISSN: 1527-9995 ISO Abbreviation: - Publication Date: 2012 Mar |
Date Detail:
|
Created Date: 2012-3-26 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 0366151 Medline TA: Urology Country: - |
Other Details:
|
Languages: ENG Pagination: - Citation Subset: - |
Copyright Information:
|
Copyright © 2012 Elsevier Inc. All rights reserved. |
Affiliation:
|
Department of Urology, Roswell Park Cancer Institute, Buffalo, New York, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Outcomes in Patients With Clinical Stage III NSGCT Who Achieve Complete Clinical Response to Chemoth...
Next Document: Cystographic Images of Youssef Syndrome: Flower on Top of the Bladder.